Laboratorios Richmond SACIF

Laboratorios Richmond SACIF FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Laboratorios Richmond SACIF (RICH.BA) as of Nov 22, 2026 is -13.37 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 138.44 % — a change of -109.65% (lower).

FCF Conversion

-13.37 %

YoY

-109.65%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Laboratorios Richmond SACIF is 2024 -13.37 % . FCF Conversion Rate (FCF/EBITDA) of Laboratorios Richmond SACIF was 2023 138.44 % . It decreases by -109.65% lower compared to the previous year.

The Laboratorios Richmond SACIF FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
-199.96 ARS
Jan 1, 2018
172.33 ARS
Jan 1, 2019
-309.80 ARS
Jan 1, 2020
-149.78 ARS
Jan 1, 2021
-370.98 ARS
Jan 1, 2022
-7,223.04 ARS
Jan 1, 2023
138.44 ARS
Jan 1, 2024
-13.37 ARS
The Laboratorios Richmond SACIF FCF Conversion history
YEARFCF ConversionYoY
-13.37 %-109.65%
138.44 %-101.92%
-7,223.04 %+1,847.03%
-370.98 %+147.68%
-149.78 %-51.65%
-309.80 %-279.77%
172.33 %-186.19%
-199.96 %+615.24%
-27.96 %-95.18%
-580.41 %+71.80%
-337.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Richmond SACIF Stock analysis

What does Laboratorios Richmond SACIF do? Laboratorios Richmond SACIF is a specialized pharmaceutical company focused on the manufacturing and marketing of medications. It was founded in 1935 and is headquartered in Buenos Aires, Argentina. The company has extensive experience in the development of medications and biological products, with expertise in pharmaceutical research and development. It has various business divisions including generics, biological medications, vaccines, oncology medications, and medical devices. The company's products range from simple painkillers and antihistamines to important medications for treating cancer and HIV. Richmond SACIF also manufactures vaccines against diseases such as Hepatitis A and B, polio, influenza, tetanus, and other infectious diseases. Additionally, the company produces a wide range of medications for treating different types of cancer and offers medical instruments and surgical devices. Its business model focuses on innovation and meeting the needs of patients, investing in research and development to develop new and innovative products. The company also has strict quality control measures to ensure the highest pharmaceutical standards. With its rich history and broad range of products, Laboratorios Richmond SACIF is a key player in the global pharmaceutical market and will continue to play an important role in improving the health of people worldwide. Laboratorios Richmond SACIF is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Richmond SACIF stock

FCF Conversion Rate (FCF/EBITDA) of Laboratorios Richmond SACIF is -13.37 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Laboratorios Richmond SACIF changed from 138.44 % to -13.37 %, representing a -109.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Laboratorios Richmond SACIF since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Laboratorios Richmond SACIF with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Laboratorios Richmond SACIF

All Key Metrics — Laboratorios Richmond SACIF